The National Institutes of Health is making a major change to how grant recipients can use their funds. | The National ...

Following the launch of two new cancer tests—plus a third planned for before the end of 2025—Exact Sciences is nudging up its ...

With the walls quickly closing in, Kronos Bio has accepted a buyout from notorious biotech acquirer Concentra Biosciences. | With the walls quickly closing in, Kronos Bio has accepted a buyout from ...

The U.S. government is putting down $500 million toward the development of a “universal” vaccine—a shot designed to protect ...

Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

The National Institutes of Health (NIH) is planning to freeze the flow of funds to institutions outside of the U.S., ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...